Tilray Medical Europe

What Tilray Medical Europe does

Tilray Medical Europe is the European operating division of Tilray Inc. (NASDAQ: TLRY), headquartered in Densborn, Germany, through Tilray Deutschland GmbH. The division produces and distributes pharmaceutical-grade medical cannabis products to patients across approximately 20 countries on five continents, with prescription-only products dispensed through pharmacy networks and major pharmaceutical wholesalers. Its primary markets are Germany, France, Ireland, Portugal, the UK, and Italy, each served by a country-specific subsidiary website, and its geographic reach extends to 18 countries receiving shipments from Germany, Portugal, and Canada.

The core product portfolio is built on GMP-certified cultivation and extraction at the Cantanhede, Portugal EU campus and the Nanaimo, Canada facility, with combined cultivation footprint exceeding 250,000 sqm and over 50 cannabis strains in THC-dominant, CBD-dominant, and balanced varieties. Products are organized into whole flower and ground flower dried cannabis, full-spectrum oral solutions produced via ethanol extraction, and purified oral solutions and capsules produced via cold extraction, each backed by stability profiles, certificates of analysis, monographs, and drug master files. The company also produces Clinical Compounds in partnership with world-leading research institutions to support clinical trials across indications including pediatric epilepsy, chemotherapy-induced neuropathy, PTSD, alcohol use disorder, essential tremor, and glioblastoma.

Revenue mechanics are driven by one-time prescription product sales through pharmacy and pharmaceutical distribution channels, with pricing not publicly disclosed and varying by country. Tilray holds three GMP certifications from Infarmed, the Portuguese national medicines authority, covering bulk dried cannabis, finished dried flower and oils, and on-site extraction and finished oil manufacturing. Distribution is supported by an enterprise field-sales motion engaging physicians and healthcare providers, plus event-driven engagement at medical conferences and with patient groups, all underwritten by an evidence-based positioning reinforced by clinical trial collaborations with Columbia University, NYU, SickKids, the University of Sydney, McGill, UBC, UC San Diego, Complutense University, and others.

Name

Tilray Medical Europe

Legal name

Tilray Deutschland GmbH

Website

https://tilraymedical.eu.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Tilray Medical Europe is the European operating division of Tilray Inc., producing and distributing GMP-certified pharmaceutical-grade medical cannabis products — dried flower and oral solutions — to patients across approximately 20 countries on five continents via pharmacy networks and pharmaceutical wholesalers, anchored by a major EU production campus in Cantanhede, Portugal.

Ownership category

akta.pro rank

Headquarters

HQ city

Densborn

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Prescription Medical Cannabis Products: Tilray generates revenue through the sale of prescription-only medical cannabis products including whole flower, ground flower, oral solutions, and capsules distributed via pharmacies and pharmaceutical distribution channels across European markets and 18 countries globally.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Tilray Medical Europe manufactures and distributes pharmaceutical-grade, prescription-only medical cannabis products including whole flower, ground flower, full-spectrum oral solutions, and purified oral solutions/capsules, produced under GMP-certified conditions in Portugal and Canada. The products are distributed through pharmaceutical wholesalers and pharmacy networks to patients across 20 countries, with additional clinical-grade study drugs supplied to leading research hospitals and universities for clinical trials.

Product overview

Tilray Medical Europe operates as a pharmaceutical-grade medical cannabis company offering a portfolio of prescription-only cannabis-based products. The product portfolio centers on two primary forms: dried flower (whole and ground) and cannabis extracts (oral solutions in full-spectrum and purified varieties). Products are categorized by cannabinoid profile (THC-dominant, CBD-dominant, or balanced) and delivered via multiple methods including drops, capsules, and whole flower for vaporization. All products undergo comprehensive testing, documentation, and quality control including stability profiles, certificates of analysis, monographs, and drug master files. The company also produces Clinical Compounds in partnership with research institutions for clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

• Whole Flower Medical Cannabis Dried cannabis flower products cultivated from over 50 strains in THC-dominant, CBD-dominant, or balanced varieties, produced under GMP-certified conditions with standardized dosing and comprehensive documentation including stability profiles and certificates of analysis. Intended for patients with qualifying medical conditions who are prescribed medical cannabis by physicians.
• Ground Flower Medicinal Cannabis Milled medical cannabis in THC-dominant, CBD-dominant, or balanced varieties, offering consistent and measured dosing for patients requiring specific consumption methods. Produced under GMP-certified conditions with full quality documentation.
• Full-Spectrum Medical Cannabis Oral Solutions Whole plant extracts produced through ethanol extraction that maintain the full profile of the cannabis plant including cannabinoids, terpenes, and flavonoids. Available as drops (dropper) or capsules in THC-dominant, CBD-dominant, or balanced varieties. Intended for patients who need oral delivery of medical cannabis with full-spectrum cannabinoid and terpene profile.
• Purified Medical Cannabis Oral Solutions Purified oral solutions and capsules produced using state-of-the-art cold extraction process designed to preserve cannabinoid and terpene content, delivering pure, aromatic pharmaceutical-grade products. Available as drops or capsules in THC-dominant, CBD-dominant, or balanced varieties for patients requiring purified cannabinoid formulations.
• Clinical Compounds Precisely crafted study drugs developed in partnership with world-leading hospitals and universities to study the efficacy of medicinal cannabis for various conditions including pediatric epilepsy, essential tremor, PTSD, and alcohol use disorder. Supplied to research partners for clinical trials, leveraging Tilray's clinical-grade isolate production capabilities.

Quantifiable outcome

• 400,000+ patients worldwide have used Tilray products
• +3 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles6 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• University of CoimbracoreStrategic or Co-development Partner · 6 December 2019Strategic research partnership combining Tilray's expertise in cannabis cultivation, manufacturing, product development and cannabinoid science with University's post-graduate opportunities in chemistry, genetics and pharmaceutical sciences. Leverages Tilray's state-of-the-art EU campus in Cantanhede and Biocant research park facilities. Partnership runs from December 2019 until 2024.
• Columbia UniversitycoreStrategic or Co-development PartnerPartnership examining effectiveness of medicinal cannabis on treating patients with Taxane-induced Neuropathy. Led by Dr. Diana Martinez (Professor of Psychiatry) and Dr. Margaret Haney (Professor of Neurobiology) at CUIMC. First human study testing medical cannabis efficacy for TIPN in breast cancer patients.
• Toronto's Hospital for Sick Children (SickKids)coreStrategic or Co-development PartnerClinical study evaluating efficacy of CBD-dominant oral solutions in children suffering from epilepsy. Tilray medicinal cannabis products used to support the led study.
• NYU School of MedicinecoreStrategic or Co-development PartnerSupporting two clinical trials led by NYU School of Medicine testing efficacy of CBD to treat patients suffering from Alcohol Use Disorder (AUD) and patients suffering from AUD comorbid with Post-Traumatic Stress Disorder.
• University of SydneyminorStrategic or Co-development PartnerClinical trials for chemotherapy-induced nausea and vomiting (CINV) and cannabinoids and driving performance study.
• Murdoch Children's Research CenterminorStrategic or Co-development PartnerStudy evaluating efficacy of medical cannabis for severe behavioral problems in children with intellectual disabilities.
• McGill UniversityminorStrategic or Co-development PartnerHIV/AIDS study and chronic obstructive pulmonary disease study involving medical cannabis products.
• University of British ColumbiaminorStrategic or Co-development PartnerPost-traumatic stress disorder (PTSD) clinical trial study.
• Complutense UniversityminorStrategic or Co-development PartnerGlioblastoma study using medical cannabis products.
• University of California-San DiegominorStrategic or Co-development PartnerEssential tremor clinical trial study.

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Jazz Pharmaceuticals (GW Pharmaceuticals): Maker of Sativex (THC:CBD oromucosal spray) and Epidiolex (CBD), pharmaceutical-grade cannabis medicines that compete with Tilray in similar therapeutic areas including epilepsy and multiple sclerosis. Represents the pharmaceutical industry's benchmark for cannabis-based prescription products.
• Canopy Growth Corporation: Major Canadian cannabis producer with significant European operations through Spectrum Therapeutics and other subsidiaries. Operates GMP-certified production facilities and distributes pharmaceutical-grade medical cannabis across Germany and other EU countries, directly competing with Tilray in the same product category and channels.
• Demecan GmbH: German medical cannabis producer with domestic cultivation and processing facilities, licensed by the German Federal Institute for Drugs and Medical Devices. Competes directly with Tilray by offering locally-produced medical cannabis to German pharmacies.
• Aurora Cannabis Inc. Canadian cannabis company with substantial European presence through Aurora Deutschland GmbH and EU GMP-certified production. Directly competes with Tilray in the German medical cannabis market with similar wholesale-distribution-to-pharmacy model and pharmaceutical-grade positioning.
• Cannamedical Pharma GmbH: German medical cannabis company importing and distributing pharmaceutical-grade cannabis products to German pharmacies, directly competing in Tilray's largest market with comparable product portfolio of flowers and extracts.

Emerging players

• Cansativa GmbH: German cannabis distribution platform that works with multiple producers to supply pharmacies. Operates as a competitor in the German medical cannabis distribution channel and could serve as either a customer or competitor to Tilray depending on commercial arrangements.
• Cantourage GmbH: German medical cannabis company specializing in bringing international producers' cannabis products to the German market. Operates as both a competitor and potential distribution partner, directly serving German pharmacies with cannabis flowers and extracts.

Broad incumbents

• Stada Arzneimittel AG: European generic pharmaceuticals company with established medical cannabis offerings in Germany through partnerships. Broader pharmaceutical portfolio but directly competes with Tilray in the German medical cannabis market through prescription distribution channels.
• Cronos Group Inc. Canadian cannabis company with global operations including Europe through subsidiary brands. Broader product portfolio including recreational cannabis, but overlaps with Tilray in pharmaceutical-grade medical cannabis distribution across multiple international markets.
• Organigram Holdings Inc. Canadian cannabis producer with international expansion ambitions. Operates broader product portfolio including recreational and medical, with overlapping GMP-certified production capabilities relevant to Tilray's pharmaceutical-grade positioning.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/tilrayportugal
• LinkedInlinkedin.com/company/tilray-medical-europe
• Instagraminstagram.com/tilrayportugal

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tilray Medical Europe